The aim of this study was to identify small molecule compounds that inhibit the kinase activity of the IGF1 receptor and represent novel chemical scaffolds, which can be potentially exploited to develop drug candidates that are superior to the existing experimental anti-IGF1R therapeuticals. To this end, targeted compound libraries were produced by virtual screening using molecular modeling and docking strategies, as well as the ligand-based pharmacophore model. High-throughput screening of the resulting compound sets in a biochemical kinase inhibition assay allowed us to identify several novel chemotypes that represent attractive starting points for the development of advanced IGF1R inhibitory compounds.
López-Calderero I., Sánchez Chávez E., García-Carbonero R. // Clin. Transl. Oncol. 2010, V.12, P.326-338
Buck E., Mulvihill M. // Expert Opin. Investig. Drugs 2011, V.20, №4, P.605-621
Belfiore A., Frasca F., Pandini G., Sciacca L., Vigneri R. // Endocrine Reviews 2009, V.30, №6, P.586-623
Pollak M. // Nat. Rev. Cancer 2012, V.12, P.159-169
Buck E., Gokhale P.C., Koujak S., Brown E., Eyzaguirre A., Tao N., Rosenfeld-Franklin M., Lerner L., Chiu M.I., Wild R. // Mol Cancer Ther. 2010, V.9, №10, P.2652-2654
Ludwig J.A., Lamhamedi-Cherradi S-E., Lee H-Y., Naing A., Benjamin R. // Cancers. 2011, V.104, №3, P.3029-3054
Yee D. // JNC I J. Natl. Cancer. Inst. 2012, V.104, №13, P.975-981
McMartin C., Bohacek R. J. // Comput.-Aided Mol. Des. 1997, V.11, №4, P.333-344
Email this article 
